(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-0.15%) $77.99
(0.37%) $2.15
(0.06%) $2 310.10
(0.36%) $26.79
(0.09%) $966.20
(-0.34%) $0.929
(-1.10%) $10.87
(-0.14%) $0.797
(0.52%) $91.61
Live Chart Being Loaded With Signals
Vectura Group Plc engages in the provision of pharmaceutical development. The company is headquartered in Chippenham, Wiltshire and currently employs 453 full-time employees...
Stats | |
---|---|
Dagens volum | 203 762 |
Gjennomsnittsvolum | 8.30M |
Markedsverdi | 0.00 |
EPS | £-0.00834 ( 2019-06-29 ) |
Last Dividend | £19.00 ( 2021-06-01 ) |
Next Dividend | £0 ( N/A ) |
P/E | 0.0800 |
ATR14 | £0 (0.00%) |
Vectura Group PLC Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Vectura Group PLC Økonomi
Annual | 2020 |
Omsetning: | £190.60M |
Bruttogevinst: | £101.40M (53.20 %) |
EPS: | £0.188 |
FY | 2020 |
Omsetning: | £190.60M |
Bruttogevinst: | £101.40M (53.20 %) |
EPS: | £0.188 |
FY | 2019 |
Omsetning: | £178.30M |
Bruttogevinst: | £95.30M (53.45 %) |
EPS: | £-0.0340 |
FY | 2018 |
Omsetning: | £160.50M |
Bruttogevinst: | £98.90M (61.62 %) |
EPS: | £-0.143 |
Financial Reports:
No articles found.
Vectura Group PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
First Dividend | £6.50 | 2019-10-14 |
Last Dividend | £19.00 | 2021-06-01 |
Next Dividend | £0 | N/A |
Payout Date | 2021-06-11 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | £25.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.69 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.35 | |
Div. Directional Score | 8.24 | -- |
Year | Amount | Yield |
---|---|---|
2019 | £0 | 0.00% |
2020 | £0 | 0.00% |
2021 | £0 | 0.00% |
2022 | £0 | 0.00% |
2023 | £0 | 0.00% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TON.L | Dividend Knight | 2023-06-01 | Annually | 32 | 1.80% | |
LTHM.L | Dividend Knight | 2023-08-03 | Semi-Annually | 33 | 0.87% | |
COA.L | Dividend Knight | 2023-10-19 | Annually | 33 | 1.79% | |
ROR.L | Dividend King | 2023-08-17 | Semi-Annually | 32 | 1.43% | |
HHI.L | Dividend King | 2023-09-14 | Quarterly | 25 | 3.58% | |
AUTO.L | Dividend Knight | 2023-08-24 | Annually | 9 | 0.79% | |
VLX.L | Dividend Knight | 2023-07-20 | Sporadic | 32 | 0.82% | |
MRCH.L | Dividend King | 2023-07-06 | Quarterly | 53 | 3.07% | |
DIVI.L | Dividend Knight | 2023-09-28 | Quarterly | 14 | 1.99% | |
SHOE.L | Dividend Knight | 2023-07-13 | Annually | 10 | 2.57% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.642 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.184 | 1.200 | 3.87 | 4.65 | [0 - 0.3] |
returnOnEquityTTM | 0.254 | 1.500 | 8.29 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.59 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 0.923 | 0.800 | 9.28 | 7.42 | [0.8 - 2.5] |
cashRatioTTM | 0.923 | 1.500 | 5.99 | 8.98 | [0.2 - 2] |
debtRatioTTM | 0.00631 | -1.500 | 9.89 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 1 314.00 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.0380 | 2.00 | 9.99 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.0181 | 2.00 | 9.99 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00771 | -1.500 | 9.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.532 | 1.000 | 4.47 | 4.47 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.689 | 1.000 | 10.00 | 10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 5.90 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.286 | 0.800 | -1.425 | -1.140 | [0.5 - 2] |
Total Score | 12.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.78 | 1.000 | 9.21 | 0 | [1 - 100] |
returnOnEquityTTM | 0.254 | 2.50 | 8.90 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.0181 | 2.00 | 9.99 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.0380 | 2.00 | 9.99 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.130 | 1.000 | 9.25 | 0 | [0.1 - 0.5] |
Total Score | 4.35 |
Vectura Group PLC
Vectura Group Plc engages in the provision of pharmaceutical development. The company is headquartered in Chippenham, Wiltshire and currently employs 453 full-time employees. The firm's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.